iRhythm Technologies

iRhythm Technologies, Inc. engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers Zio XT, is a wearable patch-based biosensor, which continuously records and stores ECG data from every patient heartbeat for up to 14 consecutive days, and Zio AT, which provides ECG data but also provides physicians with actionable notifications during the wear period. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iRhythm Technologies posts robust Q4 earnings, eyes global expansion

iRhythm Technologies delivered strong financial results, showcasing growth, innovation, and a positive EBITDA in Q4 2022. The company faces challenges in managing expenses and enhancing integration but has opportunities in new product launches, international expansion, and operational improvements.

iRhythm Technologies posts strong Q1 earnings amidst growth opportunities

iRhythm Technologies delivered robust Q1 2023 results with strong revenue growth and strategic advancements, positioning the company for sustainable expansion.
While challenges like legal inquiries and narrow profitability margins exist, the company's focus on innovation, market penetration, and financial stability bodes well for future prospects.
By capitalizing on strengths like positive clinical data, scalable growth strategies, and market opportunities, iRhythm Technologies aims to navigate challenges and drive long-term success.

iRhythm Technologies posts record revenue growth amidst regulatory challenges

iRhythm Technologies reported strong revenue growth and international expansion milestones despite challenges with FDA warning and product launch delays.
The company's focus on innovation, patient compliance, and market penetration presents opportunities for future growth and advocacy for proactive screening.
While facing challenges in product development and regulatory compliance, iRhythm remains financially robust and strategically positioned for continued success.
Navigating through challenges, iRhythm is poised to capitalize on growth opportunities and strengthen its position in the cardiac monitoring market.

iRhythm Technologies reports strong Q3 growth and eyes global expansion

iRhythm Technologies demonstrated strong financial performance in Q3 2023, with revenue growth, improved patient engagement, and market acceptance of Zio monitoring.
While facing challenges such as gross margin pressure and pricing concerns, iRhythm is focused on strategic growth initiatives and cost management for sustainable profitability.
The company is well-positioned to capitalize on opportunities like silent AFib monitoring, market expansion in Japan, and leveraging guidelines for wider screening to drive future growth.
Overall, iRhythm's Q3 results reflect resilience, strategic planning, and a positive outlook for continued success in 2023 and beyond.

iRhythm Technologies surpasses revenue expectations, eyes international expansion for growth

iRhythm Technologies demonstrated robust financial performance in Q4 2023, exceeding revenue guidance and showcasing growth in key operational metrics.
Despite regulatory challenges and external factors impacting revenue, the company's strategic strengths in product adoption and clinical evidence position it well for future growth.
Opportunities in AI, proactive screening, international expansion, and market disruption present avenues for continued expansion and market leadership.
Balancing challenges with opportunities, iRhythm aims to maintain financial sustainability while driving growth and innovation in the cardiac monitoring space.

iRhythm Technologies reports strong Q1 earnings, eyes global expansion

iRhythm Technologies delivered robust financial performance in Q1 2024, showcasing revenue growth, strategic partnerships, and a focus on sustainable operating leverage improvements.
While facing challenges such as awaiting FDA clearances and managing short-term financial losses, the company remains well-positioned with a strong financial foundation and global growth prospects.
Opportunities lie in upcoming product launches, market expansions, and the exploration of new adjacencies, positioning iRhythm for continued growth and market leadership.
Overall, iRhythm's emphasis on innovation, market expansion, and operational efficiency sets a positive trajectory for future success and shareholder value creation.

iRhythm Technologies excels in Q2 earnings, eyes global expansion

iRhythm Technologies delivered strong financial performance in Q2 2024, driven by product excellence and market expansion efforts.
While facing challenges with compliance and leadership transitions, the company remains focused on growth and operational effectiveness.
Strategic initiatives in primary care, new markets, and product launches position iRhythm well for future success and revenue growth.

iRhythm Technologies reports robust Q3 growth amidst regulatory advancements

iRhythm Technologies showed strong growth and strategic advancements in Q3 2024, focusing on global expansion and product innovation.
While facing financial challenges and regulatory hurdles, the company is actively addressing quality issues and investing in future growth.
Opportunities in international markets, product development, and financial optimization position iRhythm for long-term success and market leadership.
Investors should monitor iRhythm's progress in addressing challenges and capitalizing on growth opportunities for sustainable value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Wolfe Research 2024 Healthcare Conference.

iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against iRhythm Technologies, Inc. (NASDAQ: IRTC) on behalf of long-term stockholders following a class action complaint that was filed against iRhythm on February 6, 2024 with a Class Period from January 11, 2022, to May 30, 2023. Our investigation concerns whether the board of directors of iRhythm have breached their fiduciary duties to the company.

IRHYTHM ALERT: Bragar Eagel & Squire, P.C. is Investigating iRhythm Technologies, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q3 2024 Results Conference Call October 30, 2024 4:30 PM ET Company Participants Stephanie Zhadkevich - Director, Investor Relations Quentin Blackford - President and CEO Daniel Wilson - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Macauley Kilbane - William Blair Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG LLC David Ryman - Goldman Sachs David Rescott - Baird Richard Newitter - Truist William Plovanic - Canaccord Genuity Suraj Kalia - Oppenheimer Operator Hello, everyone, and welcome to iRhythm's Third Quarter 2024 Earnings Call. My name's Lydia, and I'll be your operator today.

iRhythm Technologies, Inc. (IRTC) Q3 2024 Earnings Call Transcript

IRhythm Technologies (IRTC) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.89 per share a year ago.

IRhythm Technologies (IRTC) Reports Q3 Loss, Tops Revenue Estimates

Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients

iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device

SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) --  iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2024.

iRhythm Technologies Announces Third Quarter 2024 Financial Results

SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that the results of the Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients with Hypertrophic Cardiomyopathy (EXAMINE-HCM) study have been published in Heart Rhythm Journal . The findings were also presented at the Heart Rhythm Society's annual meeting in 2023, and most recently, at the International HCM Summit 8 in Boston, MA (October 25-28, 2024).

Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy

iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

iRhythm Technologies (IRTC) Soars 21.7%: Is Further Upside Left in the Stock?

On Monday, the FDA approved iRhythm Technologies, Inc.'s IRTC 510(k) submission related to prior design changes to the Zio AT device via letter to file.

With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says

IRTC receives FDA 510(k) clearance for prior design modifications to its Zio AT device, reinforcing its commitment to quality and compliance.

iRhythm Technologies Stock Rises Post FDA Clearance for Zio AT

Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients

iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device

SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2024 after the close of trading on Wednesday, October 30, 2024. The company's management team will host a corresponding conference call beginning at 1:30 p.m.

iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024

PHILADELPHIA, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating iRhythm Technologies, Inc. (NASDAQ: IRTC) (“iRhythm”) on behalf of the company's long-term shareholders.

Kaskela Law LLC Announces Shareholder Investigation of iRhythm Technologies, Inc. (NASDAQ: IRTC) and Encourages Long-Term IRTC Shareholders to Contact the Firm

IRTC's Zio ECG monitoring system gets approval in Japan, marking a significant step in revolutionizing arrhythmia diagnostics with AI-powered technology.

iRhythm's Zio ECG System Gets Approval in Japan, Stock Falls

SAN FRANCISCO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that it has received regulatory approval from the Japanese Pharmaceutical and Medical Device Agency (PMDA) for the Zio® fourteen-day, long-term continuous ECG monitoring system. With regulatory approval in hand, iRhythm intends to work towards a reimbursement decision for the Zio ECG monitoring system with the Japanese Ministry of Health, Labour, and Welfare (MHLW).

iRhythm Technologies Announces Japanese Regulatory Approval of the Zio® ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence

IRTC announces initial findings demonstrating the superior real-world performance of the next-generation Zio LTCM Monitor at the HRX 2024 meeting.

iRhythm Stock Gains Following Favorable Zio Monitor Study Data

IRTC announces an exclusive license agreement with BioIntelliSense to develop and commercialize certain patented technology assets within AMC.

iRhythm Stock May Gain on Its Latest Deal With BioIntelliSense

iRhythm's next-generation Zio ® monitor demonstrated longer wear duration and analyzable time compared to the prior generation Zio ® XT device. Longer wear duration and analyzable time may further improve diagnostic yield, building upon Zio XT service's superior yield among ambulatory cardiac monitoring services as demonstrated by the prior CAMELOT study findings.

iRhythm Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio® Monitor at HRX 2024 Meeting

GUARD-AF trial results presented at European Society of Cardiology (ESC) Congress 2024 Leveraging iRhythm's Zio ® patch-based long-term continuous monitoring (LTCM), GUARD-AF is the largest randomized trial in a primary care setting to evaluate the impact of screening for undiagnosed atrial fibrillation (AF) Screening with iRhythm's Zio ® XT 1 LTCM led to increase in new diagnosis of AF (5.0% vs 3.3%) over an average follow-up of 15 months. No difference in stroke hospitalization vs usual care in the context of reduced statistical power due to truncated enrollment and follow-up.

iRhythm Technologies Announces Results of GUARD-AF Trial

IRTC launches Zio monitor in Austria, Netherlands, Spain and Switzerland, which offers 14-day continuous ECG monitoring, enhancing arrhythmia diagnosis and patient care.

iRhythm Technologies Launches Zio Monitoring Across Europe

SAN FRANCISCO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the commercial launch of its Zio monitor and Zio long-term continuous (LTCM) ambulatory ECG monitoring service in Austria, the Netherlands, Spain, and Switzerland. The Zio monitor and ZEUS (Zio ECG Utilization Software) system received the European Union's CE Marking Under Medical Device Regulation (EU MDR) in December 2023. The Zio LTCM service provides up to 14 days of continuous, uninterrupted ECG monitoring, marking a significant advancement in these countries, compared to older, commonly used 24- to 48-hour Holter monitoring services1.

iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will present at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, at 3:20 pm Eastern Time Wells Fargo 2024 Healthcare Conference on Thursday, September 5, at 8:45 am Eastern Time Baird 2024 Global Healthcare Conference on Tuesday, September 10, at 2:00 pm Eastern time Those interested in listening to the presentations may do so by accessing the live and archived webcast of the events on the “Events & Presentations” section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease.

iRhythm Technologies to Participate in Upcoming Investor Conferences in September

iRhythm Technologies (IRTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About iRhythm Technologies (IRTC) Rating Upgrade to Buy

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q1 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Stephanie Zhadkevich - Director, Investor Relations Quentin Blackford - President and CEO Brice Bobzien - Chief Financial Officer Daniel Wilson - EVP of Corporate Development and Investor Relations Conference Call Participants Margaret Andrew - William Blair Allen Gong - JPMorgan Marie Thibault - BTIG LLC David Rescott - Baird Nathan Treybeck - Wells Fargo Joanne Wuensch - Citigroup Mike Polark - Wolfe Research Ravi Misra - Truist David Saxon - Needham & Company Suraj Kalia - Oppenheimer Operator Hello all, and welcome to iRhythm Technologies Second Quarter 2024 Earnings Conference Call. My name is Lydia and I'll be your operator today.

iRhythm Technologies, Inc. (IRTC) Q2 2024 Earnings Call Transcript

IRhythm Technologies (IRTC) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.61 per share a year ago.

News for iRhythm Technologies Stock (IRTC)